Feature

From the Field

Anticipated Cost Savings with Alternate Dosing Schema of Nivolumab/Ipilimumab for the Treatment of Metastatic Melanoma

08/20/2021

Allison Kupsh, PharmD

Laura Alwan, PharmD

Eve Segal, PharmD

Kate Trieselmann, PharmD

Evan Hall, MD

Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.

Allison Kupsh, PharmD, and...

08/20/2021

Journal of Clinical Pathways

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Sarah S Mougalian, MD

Jingchuan Zhang, PhD

Talia Miller, MSW, MPH

Marjorie E Zettler, PhD, MPH

Bruce A Feinberg, DO

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways

Research Reports

US Value-Based Management of Oncology Drugs: An Explorative Study of Payer and Provider Tools to Manage the Rising Spending on Oncology Drugs

06/21/2021

Anne Runyan, BA

Daniele Severi-Bruni, MS

Kolajo Salako, BS

Oliver Walker, PhD

Anne Runyan, BA , and colleagues point out that, despite increasing cancer costs in the United States, payers’ willingness and ability to manage oncology drugs remains limited.

Anne Runyan, BA , and colleagues...

06/21/2021

Journal of Clinical Pathways

Research Reports

Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study

05/18/2021

Richard G Stefanacci, DO

Jason Yeaw, MPH

Drishti Shah, PhD

Amy Kincaid, MA

Paul N Mudd Jr, PharmD, MBA

Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.

Richard Stefanacci, DO, and...

05/18/2021

Journal of Clinical Pathways

Research Reports

Assessing Clinician Attitudes and Beliefs Around Financial Toxicity Screening in Medical Oncology Clinic

05/17/2021

Sylvia T Zhang, MS

Errol J Philip, PhD

Nichole Legaspi

Lucky Ding

Tracy Kuo Lin, MSc, PhD

Hala T Borno, MD

Sylvia Zhang, MS, and colleagues discuss the attitudes, motivation, and experiences of clinicians regarding screening for financial toxicity in a medical oncology clinical setting, identifying potential opportunities for future clinician-led...

Sylvia Zhang, MS, and colleagues...

05/17/2021

Journal of Clinical Pathways

Research Reports

Pediatric Sunscreen Coverage by Medicaid as a Primary Prevention Strategy to Reduce Melanoma Burden: A Cost-Effectiveness Analysis

04/22/2021

Dawn Queen, MD

Christine Lauren, MD

Richard D Carvajal, MD

Megan H Trager, MD

Connor Stonesifer, BA

Chin Hur, MD, MPH

Robert Stern, MD

Daniel C Malone, RPh, PhD, FAMCP

Larisa J Geskin, MD

Abstract: Melanoma treatment costs continue to rise. Sunscreen is a photoprotective tool that may reduce the incidence of melanoma but can be cost prohibitive for lower socioeconomic populations. New York State...

...

04/22/2021

Journal of Clinical Pathways

Perspectives

Patient Voices in Value-Based Cancer Care: Priorities for the Biden Administration

04/22/2021

Theresa Schmidt, MA

Jacqlyn Riposo, MBA

Tom Valuck, MD, JD

Kimberly Westrich, MA

Ethan Basch, MD, MSc

Mark McClellan, MD, PhD

Abstract: The Biden administration has an opportunity to prioritize patient perspectives in innovative value-based payment models for oncology by incorporating meaningful patient-reported measures (PRMs) and...

...

04/22/2021

Journal of Clinical Pathways

Research Report

Electronic Consultations for Subspecialists: A Potential Virtual Pathway for Patient Clinic Visits

03/15/2021

Joshua D Hickman, MHA

Megan M Colgan, BA

Michelle M L’Heureux, MD, FACP

Christopher H Lowrey, MD

Kenneth R Meehan, MD

Abstract: With the onset of the COVID pandemic, computer-assisted clinic visits and telemedicine have become a critical aspect of patient care. As a rural National Cancer Institute-designated cancer center, the...

...

03/15/2021

Journal of Clinical Pathways

Research Report

Clinical Pathways Utilization and Total Cost of Care for the Treatment of Prostate Cancer

02/22/2021

Karen A Sereday, MS

David C Boulware, MS

Sandra C Stewart, CTR

Yaroslav Shtogun, PhD

Dung-Tsa Chen, PhD

Ashley A Durand, MS

Peter AS Johnstone, MD

Julio M Pow-Sang, MD

Tracy C Simpson

Dana E Rollison, PhD

Karen K Fields, MD

Abstract: We analyzed adherence to multidisciplinary clinical pathways to understand the impact on the cost of care for patients with prostate cancer. Methods: A retrospective cohort design identified 560 patients...

...

02/22/2021

Journal of Clinical Pathways

Research Reports

The Impact of a Clinical Decision Support System for Advanced Gastric or Gastroesophageal Junction Cancer

12/16/2020

Scott Paulson, MD

Lisa M Hess, PhD

Anindya Chatterjee, PhD

Marley Boyd, MS

Kathleen M Aguilar, MPH

Astra M Liepa, PharmD

Abstract: Gastric cancer treatment heterogeneity was assessed over successive updates of clinical pathways. Methods: Patient profiles, treatment patterns, and outcomes were assessed descriptively among adult patients...

...

12/16/2020

Journal of Clinical Pathways

Current Issue

April 2024

Volume 10

Issue 2

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

Biliary Tract Cancers (BTCs) Unveiled: Expert Perspectives on Unique Challenges and Management Considerations

11/20/2023

In this supplement, learn about the complexities of biliary tract cancer (BTC) with insights from a distinguished expert panel. The supplement examines the patient journey to diagnosis and treatment of BTCs, evaluates the impact of the...

In this supplement, learn about...

11/20/2023

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Twitter

Specialties

Events

Year Round Education

HMP Global Products